Syndax Pharmaceuticals (SNDX) stock price is $13.25, up 1.22% on the day, as of Oct 20, 2026. It has a market cap of $1.18Bn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap1.18 Bn
P/E-5.33
P/S4.66
Div. Yield0.00
Total Debt (Qtr)344.03 Mn
Revenue Growth (1y) (Qtr)91.76
Add ratio to table…
About
Syndax Pharmaceuticals Inc is a commercial stage biopharmaceutical company engaged in the discovery development and commercialization of innovative cancer therapies. The company markets two FDA approved products, Revuforj (revumenib) for the treatment of relapsed or refractory acute leukemia with KMT2A translocation or NPM1 mutation and Niktimvo (axatilimab csfr) for chronic graft versus host disease after failure of at least two prior systemic therapies. Revuforj received…
Syndax Pharmaceuticals Inc is a commercial stage biopharmaceutical company engaged in the discovery development and commercialization of innovative cancer therapies. The company markets two FDA approved products, Revuforj (revumenib) for the treatment of relapsed or refractory acute leukemia with KMT2A translocation or NPM1 mutation and Niktimvo (axatilimab csfr) for chronic graft versus host disease after failure of at least two prior systemic therapies. Revuforj received its first FDA approval in November 2024 for KMT2A rearranged acute leukemia and a second approval in October 2025 for NPM1 mutated acute myeloid leukemia. Niktimvo obtained FDA approval in August 2024 based on the AGAVE 201 trial showing durable responses in patients with refractory chronic graft versus host disease. Beyond these approved therapies, Syndax advances clinical programs exploring revumenib in combination regimens for newly diagnosed leukemia, myelofibrosis and other solid tumors, while investigating axatilimab for early stage chronic graft versus host disease and idiopathic pulmonary fibrosis.
Revenue is generated primarily from product sales of Revuforj and Niktimvo in the United States where the company co commercializes Niktimvo with Incyte and retains full commercial rights to Revuforj. The partnership with Incyte provides profit sharing on US sales and entitles Syndax to receive royalties on sales outside the United States according to the collaboration agreement. In addition to product sales, Syndax has received upfront and milestone payments from its collaborations, including a non refundable cash payment of 117 million dollars from Incyte in 2021 and an upfront fee of 350 million dollars from Royalty Pharma in 2024 for the purchase of certain revenue streams. Royalty Pharma is entitled to a percentage of net sales of Niktimvo in the United States subject to a cap of 822.5 million dollars in aggregate payments. The company also earns royalty income from licensing agreements with entities such as Eddingpharm for development of entinostat in China and other Asian markets.
Syndax occupies a distinctive niche as a first in class developer of menin and CSF 1R inhibitors with Revuforj representing the only approved agent targeting the menin KMT2A interaction for acute leukemia. The menin inhibitor landscape includes competing agents such as Kobzifti (ziftomenib) which is approved only for adult NPM1 mutated AML and several preclinical candidates, giving Syndax a first mover advantage in the broader leukemia market. In the myelofibrosis space, current standard of care relies on JAK inhibitors such as ruxolitinib and fedratinib which reduce symptoms but do not significantly reverse bone marrow fibrosis, presenting an opportunity for Syndax to investigate menin inhibition to modify disease pathology. For chronic graft versus host disease, existing FDA approved therapies include ibrutinib, ruxolitinib and belomosodil which act primarily on T and B cells, whereas Syndax axatilimab targets monocyte derived macrophages to address the fibrotic component of the disease. This mechanistic differentiation may allow Syndax to achieve deeper and more durable responses in patients with fibrotic complications.
The company serves hospitals, academic medical centers, oncology clinics and transplant centers that treat patients with relapsed or refractory acute leukemia, chronic graft versus host disease and myelofibrosis. These providers rely on Syndax products to address unmet needs in patient populations with limited therapeutic options after failure of standard regimens. While specific customer names are not disclosed, the payer mix includes private insurers, government programs such as Medicare and Medicaid and managed care organizations that determine formulary coverage and reimbursement levels. Syndax also works with specialty pharmacy distributors and community oncology practices to ensure broad patient access to its therapies across the United States.
Sector:HealthcareSector rationaleSyndax Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes cancer therapies, specifically marketing FDA-approved drugs like Revuforj and Niktimvo. Its revenue is derived from product sales to hospitals and oncology clinics, as well as milestone payments and royalties from pharmaceutical collaborations.Industry:BiotechnologyBiotechnologyPrimarySyndax is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically monoclonal antibodies like Niktimvo (axatilimab). Its revenue is generated from the sales of these biologic products, as well as collaboration milestones and royalties.Classified using BQ-MICSCIK: 0001395937
Bull & bear
Investment Thesis
▲ Bull case
Syndax Pharmaceuticals is positioned to capitalize on significant untapped market potential in the frontline AML setting, where management's strategic pivot toward earlier lines of therapy—particularly through the EVOLVE-2 and REVEAL trials—could unlock a multi-billion-dollar opportunity far beyond current commercialized indications. While current RevuForge revenue is driven by relapsed/refractory NPM1 and KMT2A populations totaling approximately 6,500 annual patients, the frontline NPM1 and KMT2A AML populations represent a substantially larger addressable market, with combined incidence exceeding 10,000 new patients annually in the U.S. alone. Management highlighted that global enrollment is underway in pivotal frontline trials, with the company aiming to be first to frontline with a menin inhibitor, a differentiation that could establish RevuForge as the standard of care in newly diagnosed AML. The compelling phase 1/2 data showing high rates of MRD negativity and favorable tolerability in combination regimens—especially with Ven/Aza—supports the potential for accelerated approval pathways. Crucially, the RAVEN trial’s innovative approach of combining RevuForge with Ven/Aza in fit KMT2A patients, rather than intensive chemotherapy, addresses a key unmet need by reducing morbidity while maintaining transplant rates, which could resonate strongly with physicians and payers seeking better tolerability without sacrificing efficacy. If successful, this strategy could accelerate adoption in the frontline setting and significantly extend average treatment duration beyond the current four- to six-month range, directly driving long-term revenue per patient and reducing churn.
The Nictimvo franchise exhibits strong structural momentum that is underappreciated by the market, with persistency rates and center adoption creating a self-reinforcing growth engine that could sustain double-digit sequential growth well into 2026 and beyond. Despite being a second-mover IV drug in chronic GVHD, Nictimvo has achieved approximately 20% penetration of the third-line-plus market in just eleven months, with 90% of U.S. bone marrow transplant centers prescribing the drug and all placing repeat orders—indicating deep entrenchment in the prescriber base. Management emphasized that persistency rates of 60%-70% at month ten, with therapy durations measured in years for a subset of patients, are driving compounding revenue growth as new patient starts accumulate on a durable base. This dynamic is further strengthened by the drug’s dual action on fibrosis and inflammation, which addresses core pathophysiology in GVHD and differentiates it from prior therapies. Importantly, the collaboration revenue model with Incyte provides operating leverage: as Nictimvo net sales grow, Syndax’s share of contribution margin is expected to increase from the current 25%-30% range due to largely fixed expense bases, meaning incremental revenue flows disproportionately to the bottom line. With frontline chronic GVHD and IPF trials underway, positive data could expand Nictimvo’s utility into earlier lines of treatment and new indications, transforming it from a late-line therapy into a foundational agent with multi-indication potential and a total addressable market exceeding $5 billion across GVHD and IPF.
Real-world evidence generation, particularly from leading institutions like Moffitt Cancer Center, is creating a powerful halo effect that is accelerating physician adoption and combination use of RevuForge in ways not yet fully reflected in current prescriptions or financial guidance. The 77% overall response rate and 75% MRD negativity rate observed in relapsed NPM1/KMT2A-mutant acute leukemia patients—many of whom proceeded to stem cell transplant and resumed maintenance therapy—provides compelling validation of RevuForge’s clinical utility across genetic subtypes and in combination regimens. This evidence is especially valuable as it addresses physician skepticism about menin inhibitors’ breadth of activity and supports the growing trend of 40% combination use, which management linked to earlier lines of therapy and longer treatment durations. Crucially, the tolerability of RevuForge in combination—highlighted by real-world data showing manageable cytopenias and no unexpected safety signals—reduces a key barrier to adoption in aggressive regimens. As additional real-world series from academic centers are presented throughout 2026, this evidence could catalyze a shift in prescribing behavior toward earlier use and broader combination strategies, effectively increasing the effective patient population and average duration of therapy beyond current guidance. This organic, data-driven adoption—unprompted by major promotional campaigns—represents a stealth catalyst that could exceed internal forecasts for RevuForge uptake in 2026.
Syndax Pharmaceuticals is positioned to capitalize on significant untapped market potential in the frontline AML setting, where management's strategic pivot toward earlier lines of therapy—particularly through the EVOLVE-2 and REVEAL trials—could unlock a multi-billion-dollar opportunity far beyond current commercialized indications. While current RevuForge revenue is driven by relapsed/refractory NPM1 and KMT2A populations totaling approximately 6,500 annual patients, the frontline NPM1 and KMT2A AML populations represent a substantially larger addressable market, with combined incidence exceeding 10,000 new patients annually in the U.S. alone. Management highlighted that global enrollment is underway in pivotal frontline trials, with the company aiming to be first to frontline with a menin inhibitor, a differentiation that could establish RevuForge as the standard of care in newly diagnosed AML. The compelling phase 1/2 data showing high rates of MRD negativity and favorable tolerability in combination regimens—especially with Ven/Aza—supports the potential for accelerated approval pathways. Crucially, the RAVEN trial’s innovative approach of combining RevuForge with Ven/Aza in fit KMT2A patients, rather than intensive chemotherapy, addresses a key unmet need by reducing morbidity while maintaining transplant rates, which could resonate strongly with physicians and payers seeking better tolerability without sacrificing efficacy. If successful, this strategy could accelerate adoption in the frontline setting and significantly extend average treatment duration beyond the current four- to six-month range, directly driving long-term revenue per patient and reducing churn.
The Nictimvo franchise exhibits strong structural momentum that is underappreciated by the market, with persistency rates and center adoption creating a self-reinforcing growth engine that could sustain double-digit sequential growth well into 2026 and beyond. Despite being a second-mover IV drug in chronic GVHD, Nictimvo has achieved approximately 20% penetration of the third-line-plus market in just eleven months, with 90% of U.S. bone marrow transplant centers prescribing the drug and all placing repeat orders—indicating deep entrenchment in the prescriber base. Management emphasized that persistency rates of 60%-70% at month ten, with therapy durations measured in years for a subset of patients, are driving compounding revenue growth as new patient starts accumulate on a durable base. This dynamic is further strengthened by the drug’s dual action on fibrosis and inflammation, which addresses core pathophysiology in GVHD and differentiates it from prior therapies. Importantly, the collaboration revenue model with Incyte provides operating leverage: as Nictimvo net sales grow, Syndax’s share of contribution margin is expected to increase from the current 25%-30% range due to largely fixed expense bases, meaning incremental revenue flows disproportionately to the bottom line. With frontline chronic GVHD and IPF trials underway, positive data could expand Nictimvo’s utility into earlier lines of treatment and new indications, transforming it from a late-line therapy into a foundational agent with multi-indication potential and a total addressable market exceeding $5 billion across GVHD and IPF.
Real-world evidence generation, particularly from leading institutions like Moffitt Cancer Center, is creating a powerful halo effect that is accelerating physician adoption and combination use of RevuForge in ways not yet fully reflected in current prescriptions or financial guidance. The 77% overall response rate and 75% MRD negativity rate observed in relapsed NPM1/KMT2A-mutant acute leukemia patients—many of whom proceeded to stem cell transplant and resumed maintenance therapy—provides compelling validation of RevuForge’s clinical utility across genetic subtypes and in combination regimens. This evidence is especially valuable as it addresses physician skepticism about menin inhibitors’ breadth of activity and supports the growing trend of 40% combination use, which management linked to earlier lines of therapy and longer treatment durations. Crucially, the tolerability of RevuForge in combination—highlighted by real-world data showing manageable cytopenias and no unexpected safety signals—reduces a key barrier to adoption in aggressive regimens. As additional real-world series from academic centers are presented throughout 2026, this evidence could catalyze a shift in prescribing behavior toward earlier use and broader combination strategies, effectively increasing the effective patient population and average duration of therapy beyond current guidance. This organic, data-driven adoption—unprompted by major promotional campaigns—represents a stealth catalyst that could exceed internal forecasts for RevuForge uptake in 2026.
Syndax Pharmaceuticals’ path to profitability and sustainable growth is increasingly contingent on the success of its pipeline programs, particularly axatilamab in IPF, yet the company provided minimal detail on risks associated with trial execution or competitive differentiation during the Q&A, creating uncertainty about near-term catalysts. While management highlighted the completion of enrollment in the MaxSpire phase 2 trial and expressed confidence in a 40 mL FVC difference as a meaningful benchmark, they did not address potential challenges such as patient recruitment variability in IPF trials, the high placebo response rates historically seen in fibrotic lung disease studies, or the risk that the annualized FVC endpoint may not translate to clinically meaningful outcomes despite statistical significance. The reliance on a surrogate endpoint (FVC) rather than mortality or hospitalization introduces regulatory risk, especially given the mixed track record of antifibrotics in IPF where some agents failed to demonstrate clear clinical benefit despite positive biomarker data. Furthermore, the company offered no insight into how axatilamab’s subcutaneous formulation—cited as a potential differentiator—would navigate formulation stability, manufacturing scalability, or payer reimbursement hurdles, all of which could delay or complicate phase 3 plans even with positive phase 2 data. With no discussion of contingency plans or alternative indications if the IPF trial underperforms, the market may be overestimating the likelihood of axatilamab contributing meaningfully to valuation in the near term.
The company’s financial outlook assumes stable operating expenses and no need for additional capital, but this projection may be overly optimistic given the escalating costs associated with advancing multiple pivotal trials simultaneously across frontline AML, chronic GVHD, and IPF, which could strain the current cash runway despite the reported $394 million year-end balance. Management guided to approximately $400 million in combined R&D and SG&A expenses for 2026, excluding $50 million in non-cash stock compensation, yet provided no breakdown of how these costs are allocated across programs or what contingencies exist for trial delays, protocol amendments, or unexpected safety findings that could necessitate additional spending. The pursuit of frontline registration programs—including EVOLVE-2, REVEAL, and RAVEN—alongside ongoing phase 2/3 trials for Nictimvo in frontline GVHD and axatilamab in IPF, represents a significant ramp-up in clinical development activity that may not align with the assumption of flat quarterly expenses. Moreover, the expectation that Nictimvo collaboration margins will improve over time relies heavily on the assumption that commercial and distribution expenses remain largely fixed, but scaling to support earlier-line indications or new geographies could trigger incremental investments in field staff, medical affairs, and market access that would erode this leverage. Without explicit discussion of expense flexibility or scenario planning for higher-than-expected investment needs, the path to profitability appears predicated on a narrow set of optimistic assumptions.
Competitive pressures in both the menin inhibitor and antifibrotic spaces are likely intensifying in ways that management downplayed, posing a material risk to Syndax’s market share gains and pricing power, particularly as larger pharmaceutical companies enter these spaces with greater resources and established commercial infrastructure. While management expressed confidence in dominating the NPM1 AML space despite a competitor’s recent entry, they offered no qualitative or quantitative assessment of that competitor’s prescribing trends, formulary positioning, or potential for aggressive pricing or rebating strategies that could undermine Syndax’s market access gains—such as the 97% formulary coverage achieved in just four months. Similarly, in the GVHD and IPF landscapes, the company did not address how emerging therapies targeting overlapping pathways (e.g., other CSF1R inhibitors, novel antifibrotics, or JAK inhibitors in development) might erode Nictimvo’s or axatilamab’s differentiation, especially if those agents offer superior dosing convenience, oral administration, or broader indications. The reliance on physician comfort and real-world evidence as a moat may be insufficient if competitors generate comparable or better clinical data with stronger commercial backing. Given that Syndax is still early in its commercial evolution, its ability to withstand sustained competitive pressure—especially in the form of payer steering or institutional preference shifts—remains untested, and the lack of discussion around defensive strategies during Q&A suggests this risk is not being actively managed.
Syndax Pharmaceuticals’ path to profitability and sustainable growth is increasingly contingent on the success of its pipeline programs, particularly axatilamab in IPF, yet the company provided minimal detail on risks associated with trial execution or competitive differentiation during the Q&A, creating uncertainty about near-term catalysts. While management highlighted the completion of enrollment in the MaxSpire phase 2 trial and expressed confidence in a 40 mL FVC difference as a meaningful benchmark, they did not address potential challenges such as patient recruitment variability in IPF trials, the high placebo response rates historically seen in fibrotic lung disease studies, or the risk that the annualized FVC endpoint may not translate to clinically meaningful outcomes despite statistical significance. The reliance on a surrogate endpoint (FVC) rather than mortality or hospitalization introduces regulatory risk, especially given the mixed track record of antifibrotics in IPF where some agents failed to demonstrate clear clinical benefit despite positive biomarker data. Furthermore, the company offered no insight into how axatilamab’s subcutaneous formulation—cited as a potential differentiator—would navigate formulation stability, manufacturing scalability, or payer reimbursement hurdles, all of which could delay or complicate phase 3 plans even with positive phase 2 data. With no discussion of contingency plans or alternative indications if the IPF trial underperforms, the market may be overestimating the likelihood of axatilamab contributing meaningfully to valuation in the near term.
The company’s financial outlook assumes stable operating expenses and no need for additional capital, but this projection may be overly optimistic given the escalating costs associated with advancing multiple pivotal trials simultaneously across frontline AML, chronic GVHD, and IPF, which could strain the current cash runway despite the reported $394 million year-end balance. Management guided to approximately $400 million in combined R&D and SG&A expenses for 2026, excluding $50 million in non-cash stock compensation, yet provided no breakdown of how these costs are allocated across programs or what contingencies exist for trial delays, protocol amendments, or unexpected safety findings that could necessitate additional spending. The pursuit of frontline registration programs—including EVOLVE-2, REVEAL, and RAVEN—alongside ongoing phase 2/3 trials for Nictimvo in frontline GVHD and axatilamab in IPF, represents a significant ramp-up in clinical development activity that may not align with the assumption of flat quarterly expenses. Moreover, the expectation that Nictimvo collaboration margins will improve over time relies heavily on the assumption that commercial and distribution expenses remain largely fixed, but scaling to support earlier-line indications or new geographies could trigger incremental investments in field staff, medical affairs, and market access that would erode this leverage. Without explicit discussion of expense flexibility or scenario planning for higher-than-expected investment needs, the path to profitability appears predicated on a narrow set of optimistic assumptions.
Competitive pressures in both the menin inhibitor and antifibrotic spaces are likely intensifying in ways that management downplayed, posing a material risk to Syndax’s market share gains and pricing power, particularly as larger pharmaceutical companies enter these spaces with greater resources and established commercial infrastructure. While management expressed confidence in dominating the NPM1 AML space despite a competitor’s recent entry, they offered no qualitative or quantitative assessment of that competitor’s prescribing trends, formulary positioning, or potential for aggressive pricing or rebating strategies that could undermine Syndax’s market access gains—such as the 97% formulary coverage achieved in just four months. Similarly, in the GVHD and IPF landscapes, the company did not address how emerging therapies targeting overlapping pathways (e.g., other CSF1R inhibitors, novel antifibrotics, or JAK inhibitors in development) might erode Nictimvo’s or axatilamab’s differentiation, especially if those agents offer superior dosing convenience, oral administration, or broader indications. The reliance on physician comfort and real-world evidence as a moat may be insufficient if competitors generate comparable or better clinical data with stronger commercial backing. Given that Syndax is still early in its commercial evolution, its ability to withstand sustained competitive pressure—especially in the form of payer steering or institutional preference shifts—remains untested, and the lack of discussion around defensive strategies during Q&A suggests this risk is not being actively managed.